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ABSTRACT
Introduction: Orthopedic surgeries are among
the most common and most painful surgeries
performed. A multimodal analgesic approach
is recommended to reduce opioid consump-
tion, provide effective pain relief, and improve
outcomes following surgery. This study
examined the efficacy and opioid-sparing
effects of parecoxib following major orthope-
dic surgery.
Methods: This subset analysis of a large, mul-
ticenter, randomized, double-blind,
placebo-controlled study of parecoxib exam-
ined treatment effects on postoperative pain
severity, pain interference with function, opioid
consumption, occurrence of opioid-related
symptoms, safety, and patient satisfaction fol-
lowing major orthopedic surgery.
Results: Pain scores were significantly lower in
the parecoxib group (n = 142) compared with
placebo (n = 139) on day 2 (-22%; p\0.001)
and day 3 (-17%; p = 0.004). Pain interference
with function scores were also significantly
lower in the parecoxib group on day 2 (-32%;
p\0.001) and day 3 (-27%; p = 0.003) relative
to placebo. Additionally, significantly less sup-
plemental morphine was required in the pare-
coxib group relative to placebo through 24 h
(-28%; p = 0.008) and 48 h (-33%; p\0.001).
Patients in the parecoxib group had a reduced
risk of experiencing opioid-related symptoms
including fatigue, drowsiness, inability to con-
centrate, confusion, nausea, constipation, and
confusion on day 2 and/or day 3. Finally, more
patients receiving parecoxib (42%) rated treat-
ment as ‘‘excellent’’ compared to those receiv-
ing placebo (21%).
Conclusions: These findings support the use of
parecoxib for the management of pain follow-
ing major orthopedic surgery.
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Orthopedic surgeries are among the most com-
mon major surgeries and their incidence has
grown over the past 15 years [1–3]. In 2011
there were approximately 645,062 total knee
replacements, 465,070 spinal fusions, and
306,600 total hip replacements in the USA
alone [2]. These types of surgeries, particularly
knee and hip replacements, are expected to
dramatically increase over the next 15 years [3].
Orthopedic surgeries, however, are also among
the most painful surgeries, and moder-
ate-to-severe postoperative pain is not uncom-
mon [4–6]. Pain management is of utmost
importance in the early stages after total knee
and hip arthroplasty, because prompt and
extensive physical rehabilitation and activity
are encouraged, but may be restrained by pain.
Indeed, though surgeries such as total joint
replacement have a high success rate, they are
underutilized, in part, because of fear of pain
[7, 8]. Furthermore, there is a high rate of
patient dissatisfaction following total knee
arthroplasty, and pain is the most significant
predictor of dissatisfaction [9]. Thus, the selec-
tion and use of effective analgesics are impor-
tant considerations following major orthopedic
procedures to ensure that the patient can rest at
night and tolerate therapy during the day.
Appropriate pain control after orthopedic
surgeries can enhance early functional recovery
[10, 11]. Managing acute pain begins in the
preoperative period and continues throughout
the postoperative phase. Multimodal analgesia
can provide superior control of postsurgical
pain compared with a traditional opioid anal-
gesic regimen [10, 12]. Although opioids are
effective against moderate-to-severe pain, they
are frequently associated with a variety of
unwanted side effects including drowsiness,
confusion, nausea, itching, and constipation
[13–15]. These side effects add stress to the
patient and may require them to undergo sup-
plementary treatments for the management of
these effects, further delaying mobilization and
increasing recovery/hospitalization times
[16, 17]. In addition, though they are effective
for pain at rest, opioids are less effective for
movement-related pain which may be
problematic during physical rehabilitation and
early mobilization strategies [18, 19]. As a result,
to reduce overall opioid consumption and the
occurrence of opioid-associated side effects,
current treatment guidelines recommend a
multimodal treatment strategy that incorpo-
rates non-steroidal anti-inflammatory drugs
(NSAIDs), cyclooxygenase-2 inhibitors (COX-
IBs), and/or acetaminophen to supplement
opioid use [20]. Multimodal analgesia has pro-
ven to be provide adequate pain control, assist
in early recovery, and even allow for same-day
discharge after total knee and hip replacement
surgery [11].
Parecoxib, an injectable COXIB with
long-acting duration, has been approved in over
80 countries as analgesia to reduce postopera-
tive pain. Since parecoxib is selective for
cyclooxygenase-2 inhibition, it poses less risk
for bleeding and gastrointestinal-related adverse
events as compared to nonselective NSAIDs
[21–24]. It also does not pose a risk for many of
the central nervous system-related side effects
that are associated with opioids. However, there
are few studies in the literature that examine
the analgesic efficacy and opioid-sparing effects
of postoperative parecoxib administration in
patients undergoing major orthopedic surgery.
The current analysis, therefore, examines the
efficacy and opioid-sparing effects of parecoxib
following major orthopedic surgery [25].
METHODS
Data Source
Data were derived from a multicenter, ran-
domized, double-blind, placebo-controlled
clinical trial that examined the safety and effi-
cacy of parecoxib followed by valdecoxib for
postoperative pain resulting from a variety of
non-cardiac surgeries [25]. The study was con-
ducted at 113 site in 14 countries including the
USA, Canada, Chile, Argentina, Australia, New
Zealand, Bulgaria, Czech Republic, Poland,
Romania, Ukraine, Finland, Israel, and South
Africa. Here, we examine a large subset of
patients from this clinical trial that includes all
patients who underwent major orthopedic
Pain Ther
surgery. The study was approved by an institu-
tional review board or independent ethics
committee at each investigational center, and
patients provided written informed consent
before participation. The study was conducted
in compliance with the Declaration of Helsinki
of 1964, as revised in 2013, and all International
Conference on Harmonization Good Clinical
Practice Guidelines. Detailed methods of the
trial can be found in the original publication
but a brief summary is given below [25].
Following surgery, patients were admitted to
the recovery room. Here, upon recovery from
anesthesia, patients who met all pre-, intra-, and
postoperative inclusion criteria were random-
ized in a double-blind manner to receive pare-
coxib/valdecoxib or matching placebo. On day
1 (the day of surgery and recovery from anes-
thesia) all patients randomized to the pare-
coxib/valdecoxib group received an initial
40-mg IV dose of parecoxib. These patients then
received parecoxib 20 mg (IV or IM) every 12 h
through at least day 3. Once the patient could
tolerate oral medication, but no earlier than day
4, they received 20-mg doses of oral valdecoxib
through day 10, and patients assigned to receive
placebo did so on a matching schedule. It
should be noted that all assessments in this
analysis were done when patients were receiv-
ing parecoxib (prior to switching to valdecoxib)
(Table 1). As such the parecoxib/valdecoxib
group will simply be referred to as the parecoxib
group from here on. Patients with inadequate
pain relief were allowed supplemental analgesia
that consisted of IV administration of morphine
sulfate through patient-controlled analgesia
(PCA) or in IV/IM bolus as needed. No other
supplemental analgesia was permitted.
Efficacy Assessments Included in Current
Analysis
Patient demographics and baseline characteris-
tics were summarized descriptively in all ran-
domized patients.
Summed pain intensity over 24 h (SPI-24)
was calculated on day 2 (the day after surgery)
and day 3 for each treatment group as described
previously and was derived from daily
patient-reported pain assessments that ranged
in score from 0 = none to 3 = severe pain [25].
An analysis of variance (ANOVA) model with
treatment and country as factors and a last
observation carried forward (LOCF) approach to
missing data were used to compare SPI scores
between the placebo and parecoxib treatment
groups.
Composite pain interference with function
scores were derived from five items of the pain
interference with function question of the
modified Brief Pain Inventory-short form
(mBPI-sf) [26]. The five items included pain
interference with general activity, mood, walk-
ing ability, relations with others, and sleep.
Scores on day 2 (the day after surgery) and day 3
were compared between parecoxib and placebo
treatment groups using a general linear model,
with treatment and country as factors. A LOCF
approach was used to account for missing data.
Table 1 Administration of parecoxib
Treatment Schedule
40 mg IV parecoxib One dose on day 1 (the day of surgery following recovery from anesthesia)
20 mg IV or IM parecoxib At 8:00 P.M. or midnight on day 1 and then every 12 h through at least day 3a
Patients assigned to placebo received a matching placebo administered in the same manner as parecoxib
a Patients who received their ﬁrst dose of 40 mg IV parecoxib on day 1 between 8:00 A.M. and 12:00 P.M. received their
ﬁrst dose of 20 mg IV/IM parecoxib at 8:00 P.M. on day 1. Patients who received their ﬁrst dose of 40 mg IV parecoxib on
day 1 between 12:01 P.M. and 6:00 P.M. received their ﬁrst dose of 20 mg IV/IM parecoxib at midnight on day 1. Patients
who received their ﬁrst dose of 40 mg IV parecoxib after 6:01 P.M. on day 1 did not receive a 20 mg IV/IM dose of
parecoxib on day 1. All patients received a 20 mg IV/IM dose of parecoxib at 8:00 A.M. on Day 2 and then every 12 h
according to the schedule in Table 1
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On day 2 (24 h post initial dose of study
treatment) and day 3 (48 h post initial dose of
study treatment), the cumulative amount of
supplemental morphine consumed was deter-
mined and compared between the parecoxib
and placebo groups. This comparison employed
an ANOVA model with treatment and country
as factors.
The occurrence of opioid-related symptoms
(drowsiness, retching/vomiting, confusion,
dizziness, itching, difficulty with urination,
constipation, inability to concentrate, nausea,
and fatigue) was determined on day 2 (the day
after surgery) and day 3 using the Opioid-Re-
lated Symptom Distress Scale (ORSDS) [14]. The
relative risk (RR; parecoxib versus placebo) was
calculated for each particular symptom on the
basis of the percentage of patients experiencing
that symptom in each treatment group. Statis-
tical significance was assessed using a Fisher’s
exact test. An RR (parecoxib versus placebo) of
experiencing C1, C2, and C3 opioid-related
symptoms was also determined for day 2.
Physicians and patients evaluated the study
medication at the time of transition from IV/IM
to oral dosing using a scale from 1 = poor to
4 = excellent. These scores were compared
between parecoxib and placebo treatment
groups using a Cochran–Mantel–Haenszel test,
controlling for country.
Safety was assessed by examining the occur-
rence of treatment-related adverse events (AEs).
AEs were monitored for 7 days after receiving
last dose, so both acute and non-acute events
were recorded. The frequency of the most
common AEs (those occurring in C2% of
patients in either treatment group) was calcu-
lated for the placebo and parecoxib groups and
summarized descriptively. NSAIDs and COXIBs
have been associated with specific adverse
events such as gastrointestinal events, cardio-
vascular events, and bleeding. Therefore, we
also examined the frequency of these specific
events by searching all treatment-emergent AEs
using the Standardized Medical Dictionary for
Regulatory Activities (version 19.0) Queries of
embolic and thrombotic events; gastrointestinal
perforation, ulceration, hemorrhage or
obstruction; hemorrhage terms (excluding lab-
oratory terms).
All statistical analyses were performed using
the modified intent-to-treat population, which
consisted of all randomized patients who
received at least one dose of study medication.
Analyses were performed using Statistical Anal-
ysis System software (SAS Institute, Cary, NC,
USA). It should be noted that all assessments in
this analysis were done at a time when patients
in the parecoxib group were receiving IV or IM
parecoxib and had not yet switched to oral
valdecoxib.
RESULTS
The number of patients in the orthopedic subset
who were randomized to treatment was 139 for
the placebo group and 142 for the parecoxib
group (Fig. 1). Basic patient demographics were
similar between the placebo and parecoxib
treatment groups (Table 2). The patient popu-
lation was predominantly white and had a
median age of approximately 61 years. The
most common surgeries in both treatment
groups were procedures involving the knee
(placebo = 52.5%; parecoxib = 46.5%), fol-
lowed by procedures involving the hip
(placebo = 21.6%; parecoxib = 31.0%) or the
neck/spine (placebo = 15.8%; pare-
coxib = 12.7%). Over 85% of all knee proce-
dures were total knee replacements and over
95% of the hip procedures were total hip
replacements. The number of patients receiving
at least one dose of study medication was 138 in
Fig. 1 Flow of patients through the trials
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the placebo group and 138 in the parecoxib
group.
Parecoxib demonstrated a significant anal-
gesic effect on day 2 (the day after surgery), with
mean SPI-24 scores 22% (p\0.001) lower in the
parecoxib group relative to placebo (Fig. 2). This
corresponds to an absolute difference of 7.7
points, on a scale from 0 to 72, between the
treatment groups. Likewise, SPI-24 scores were
also significantly lower in the parecoxib group,
compared with placebo, on day 3 (Fig. 2). The
absolute difference between the groups was 4.9
points, which corresponds to a 17% (p = 0.004)
reduction in the parecoxib group relative to
placebo.
In addition to lower pain intensity scores,
parecoxib treatment also provided significant
improvements in patient function compared
with placebo (Fig. 3). Composite pain interfer-
ence with function scores were reduced by 32%
(p\0.001) on day 2 (the day after surgery) and
27% (p = 0.003) on day 3 relative to placebo.
These percentages correspond to an absolute
difference of 1.6 and 0.9 points (on a scale from
0 to 10) on day 2 and day 3, respectively.
On day 2 (24 h post initial dose of study
medication) and day 3 (48 h post initial dose of
study medication), treatment with parecoxib
was associated with a significant opioid-sparing
effect (Fig. 4). Patients in the parecoxib group
consumed 28% less morphine at 24 h
(p = 0.008) and 33% less morphine at 48 h
(p\0.001) relative to placebo. This corresponds
to absolute reductions of 9.9 and 22.8 morphine
equivalents at 24 and 48 h, respectively.
Patients receiving parecoxib also had a
reduced risk of experiencing opioid-related
symptoms on day 2 (the day after surgery) and
day 3 compared to patients receiving placebo
(Table 3). Specifically, the risk of experiencing
fatigue, drowsiness, inability to concentrate,
and confusion was significantly reduced on
both day 2 (the day after surgery) and day 3 in
the parecoxib group compared with placebo. In
addition, the risk of experiencing nausea, con-
stipation, and retching/vomiting was signifi-
cantly reduced on day 3 but not day 2 in the
parecoxib group relative to placebo. The risks of
dizziness, itching, and difficulty with urination
were not significantly different between treat-
ment groups on either day 2 or day 3. The
overall relative risk (RR) of experiencing C1
(RR = 0.71; p\0.010), C2 (RR = 0.55;
p\0.001), and C3 (RR = 0.33; p\0.001) opi-
oid-related symptoms was significantly lower
with parecoxib compared with placebo on day
3.
Both patient (Fig. 5a) and physician (Fig. 5b)
evaluations of study medication scores were
significantly different between the parecoxib
and placebo groups at the time of transition







Mean (SD) 58.4 (13.9) 59.0 (14.4)
Median 60.5 60.8
Range 22–81 19–81
Gender, n (%) 0.475
Male 65 (45.8) 70 (50.4)
Female 77 (54.2) 69 (49.6)
Race, n (%) 0.924
White 131 (92.3) 130 (93.5)
Black 9 (6.3) 7 (5.0)
Not listed 2 (1.4) 2 (1.4)
BMI, kg/m2 0.591
Mean (SD) 29.8 (5.0) 30.2 (4.7)
Median 29.7 29.7
Surgery type, n (%) 0.262
Knee 66 (46.5) 73 (52.5)
Hip 44 (31.0) 30 (21.6)
Neck/spine 18 (12.7) 22 (15.8)
Ankle/foot/bunion 9 (6.3) 6 (4.3)
Arm/shoulder/hand 4 (2.8) 8 (5.8)
Other 1 (0.7) 0 (0.0)
Percentages in the table may not add up to 100 because of
rounding
SD standard deviation, BMI body mass index
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from IV/IM to oral dosing (both p\0.001). A
greater percentage of patients (42%) and
physicians (46%) in the parecoxib group rated
their treatment as ‘‘excellent’’ compared with
patients (21%) and physicians (19%) in the
placebo group. Likewise, fewer patients (13%)
and physicians (8%) in the parecoxib group
rated their treatment as ‘‘poor’’ or ‘‘fair’’
compared with patients (32%) and physicians
(35%) in the placebo group.
Treatment-emergent AEs during the IV/IM
phase occurred with a similar frequency in the
placebo (55.8%) and parecoxib (58.7%) groups.
The most common treatment-emergent AEs for
each group are shown in Table 4. Of these AEs,
nausea (parecoxib = 17.4%; placebo = 15.9%),
vomiting (parecoxib = 9.4%; placebo = 5.8%),
pruritus (parecoxib = 7.2%; placebo = 4.3%),
insomnia (parecoxib = 6.5%; placebo = 2.9%),
dizziness (parecoxib = 2.9%; placebo = 0.7%),
headache (parecoxib = 2.9%; placebo = 2.2%),
fatigue (parecoxib = 2.2%; placebo = 0.0%),
and sleep disorder (parecoxib = 2.2%;
placebo = 0.0%) occurred more frequently in
the parecoxib group relative to placebo.
NSAIDs and COXIBs have been associated
with a variety of specific adverse events
including cardiovascular embolic and throm-
botic events; gastrointestinal ulceration, bleed-
ing, perforation, or hemorrhage; and bleeding.
No instances of these types of events were
reported among parecoxib-treated patients,
with the following exception. There was one
instance of myocardial infarction in a 74--
year-old man reported in the parecoxib group
that resulted in death of the subject; this event
was deemed unrelated to the study drug or the
use of opioids by the site investigator. The
patient had been permanently withdrawn from
Fig. 2 Mean SPI-24 scores following surgery. **p\0.001;
*p\0.010 versus placebo. Day 2 is the day after surgery.
SD standard deviation, SPI-24 summed pain intensity over
24 h
Fig. 3 Mean mBPI-sf composite pain interference with
function scores following surgery. **p\0.001 versus
placebo; *p\0.010 versus placebo. Day 2 is the day after
surgery. SD standard deviation, mBPI-sf modiﬁed brief
pain inventory-short form
Fig. 4 Cumulative morphine consumption following ini-
tial dose of study medication. **p\0.001 versus placebo;
*p\0.010 versus placebo. SD standard deviation
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the study because of elevated creatinine and
urea nitrogen in the blood after 2 days of
treatment (the day after surgery). The myocar-
dial infarction occurred 3 days after discontin-
uation of treatment.
DISCUSSION
Pain control is directly related to fast recovery,
early rehabilitation, and patient satisfaction
after orthopedic surgeries such as total joint
replacement [10–12]. In this subset analysis of
patients undergoing major orthopedic surgery,
postoperative administration of parecoxib
resulted in significantly lower pain scores rela-
tive to placebo on day 2 (the day after surgery)
and day 3 following surgery. Pain interference
with function scores, which are a composite
score that examines how pain affects general
activity, mood, walking ability, relations with
others, and sleep, were also significantly better
with parecoxib compared with placebo. These
data demonstrate that parecoxib provides clin-
ically meaningful improvement in pain and
patient function following orthopedic surgery.
Indeed, a large percentage of both patients
(42%) and physicians (46%) rated parecoxib
treatment as ‘‘excellent’’ during the study.
Opioids can elicit a variety of adverse events
that slow patient recovery and rehabilitation,
and current treatment guidelines recommend a
multimodal treatment approach that incorpo-
rates other agents to provide supplemental
analgesia and reduce overall opioid consump-
tion [13, 15–17, 20, 27]. In the current study,
parecoxib significantly reduced overall postop-
erative opioid consumption, compared to pla-
cebo, and decreased the occurrence of multiple
opioid-related adverse events.
Pain and pain control following orthopedic
surgery vary according to procedure and the
type of anesthesia utilized [28]. Pain control
after hip replacement, for example, is
Table 3 Frequency of opioid-related symptoms following surgery









RRa (95% CI) p valuea
Fatigue 27 48 0.58 (0.41, 0.80) \0.001 23 42 0.54 (0.37, 0.79) \0.010
Drowsiness 39 58 0.67 (0.51, 0.87) \0.010 22 44 0.51 (0.35, 0.74) \0.001
Inability to
concentrate
16 32 0.50 (0.32, 0.80) \0.010 8 22 0.35 (0.18, 0.69) \0.010
Nausea 22 30 0.76 (0.50, 1.15) NS 4 14 0.28 (0.11, 0.72) \0.010
Dizziness 12 17 0.72 (0.39, 1.30) NS 9 12 0.69 (0.33, 1.42) NS
Constipation 22 13 1.63 (0.94, 2.83) NS 18 34 0.53 (0.34, 0.83) \0.010
Itching 21 20 1.09 (0.68, 1.77) NS 13 13 0.99 (0.53, 1.86) NS
Difﬁculty with
urination
4 8 0.49 (0.17, 1.40) NS 2 3 0.73 (0.17, 3.21) NS
Confusion 2 8 0.20 (0.04, 0.87) \0.050 2 9 0.27 (0.08, 0.93) \0.050
Retching/
vomiting
13 18 0.71 (0.40, 1.28) NS 0b 6 – –
NS non-signiﬁcant, RR relative risk
a Parecoxib compared to placebo
b It was not possible to calculate the RR since no patients in the parecoxib group experienced retching/vomiting
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considered easier than after knee replacement
[29, 30]. In addition, pain and recovery follow-
ing total joint replacement can be significantly
worse using general anesthesia compared with
spinal or epidural approaches [31, 32]. Our
study is the first, to our knowledge, to combine
several types of orthopedic procedures and
analyze them as a single heterogeneous group.
However, our findings are in broad agreement
with previous placebo-controlled studies of
parecoxib in specific orthopedic surgery models.
For example, significant improvements in
postoperative pain have been associated with
multiple dose parecoxib in patients undergoing
total hip arthroplasty [33, 34], total knee
arthroplasty [35, 36], and a variety of spinal
procedures including spinal fusion [37]. In
nearly all these trials, parecoxib also reduced
total postoperative opioid consumption com-
pared to placebo [33, 35–37].
In our clinical trial setting, it is recognized
that AEs can result from the use of study treat-
ment, rescue opioids (which were available to
both placebo and parecoxib treatment groups),
or the surgical procedure itself. In our analysis,
the overall frequency of AEs was similar in the
parecoxib and placebo groups and, with the
exception of nausea, no specific AE was reported
in more than 10% of patients in either treat-
ment group. Certain AEs, however, occurred
more frequently in the parecoxib group
including nausea, vomiting, pruritus, insomnia,
dizziness, headache, fatigue, and sleep disorder.
Our study is also limited in that it was a
subset analysis of patients from a clinical trial
that was not powered specifically to look at the
outcomes assessed here [25]. However, the
number of patients included in our analysis is
large and on par with previous trials of pare-
coxib for postoperative pain. Our analysis is also
limited in that the original clinical trial did not
specifically assess movement-related pain,
which is particularly important in patients fol-
lowing orthopedic surgery. Parecoxib has been
shown to relieve movement-related pain fol-
lowing gynecological surgery [38, 39] and total
hip arthroplasty (in press). Additionally, a pre-
vious placebo-controlled study has shown that
parecoxib results in improved range of motion,
relative to placebo, following total knee
replacement [35].
The patients included in our analysis
received parecoxib postoperatively, though
studies have shown that traditional NSAIDs and
some COXIBs may provide preemptive analge-
sia and demonstrate greater pain relief when
administered 30–45 min prior to surgery
[40, 41]. Traditional NSAIDs, however, inhibit
platelet function and may increase bleeding
time. Parecoxib does not affect platelet func-
tion, making it a potentially attractive preop-
erative analgesic option [21, 22]. Though
Fig. 5 Patient (a) and physician (b) global evaluation of study medication scores at the time of transition from IV/IM to
oral dosing
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parecoxib provides an analgesic benefit when
administered preoperatively or postoperatively,
few studies have compared timing of parecoxib
administration, and the results are mixed. Pre-
operative administration of parecoxib provided
greater pain relief compared to postoperative
administration in trials of general surgery and
total hip replacement [42, 43]. In another study
of total hip replacement, however, there was no
significant difference in pain severity or total
opioid consumption between pre- and postop-
erative administration of parecoxib [44]. Addi-
tionally, there was no difference in analgesia
and opioid-related adverse events between pre-
and postoperative administration of parecoxib
in patients following colorectal surgery [45].
Further studies are required to determine
whether preoperative administration of pare-
coxib offers any advantages over postoperative
administration in patients undergoing ortho-
pedic procedures. Currently, Procedure Specific
Postoperative Pain Management (PROSPECT)
guidelines recommend COXIBs, such as pare-
coxib, as postoperative analgesia following total
knee or hip arthroplasty [28].
CONCLUSION
Overall, postoperative administration of pare-
coxib provided significant analgesic and opi-
oid-sparing effects in our analysis. Thus, the
data suggest that parecoxib is a good option for
patients following orthopedic surgeries, which
often depend on early mobilization and physi-
cal rehabilitation for successful outcomes.
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